Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16658438 | 0.85 | MAPT (0.44) | MAPTL3MBTL1HPGDTDP1ALDH1A1 | |
| SCHEMBL10050063 | 0.82 | ALDH1A1 (0.51) | MAPTL3MBTL1HPGDTDP1ALDH1A1 | |
| SCHEMBL16650492 | 0.81 | KDM4E (0.40) | MAPTL3MBTL1HPGDALDH1A1LMNA | |
| SCHEMBL1391227 | 0.80 | MAPT (0.49) | MAPTL3MBTL1HPGDTDP1ALDH1A1 | |
| SCHEMBL1390954 | 0.80 | MAPT (0.49) | MAPTL3MBTL1HPGDTDP1ALDH1A1 | |
| SCHEMBL21191023 | 0.80 | HRH3 (0.39) | L3MBTL1ALDH1A1KMT2AGFER | |
| SCHEMBL18994421 | 0.79 | MAPT (0.47) | MAPTL3MBTL1HPGDTDP1ALDH1A1 | |
| SCHEMBL16658437 | 0.79 | MAPT (0.47) | MAPTL3MBTL1HPGDTDP1ALDH1A1 | |
| SCHEMBL20819545 | 0.76 | LMNA (0.49) | MAPTL3MBTL1HPGDTDP1ALDH1A1 | |
| SCHEMBL2574095 | 0.76 | MAPT (0.48) | MAPTL3MBTL1HPGDTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | MAPT 2462/4885L3MBTL1 1519/4885HPGD 1266/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | MAPT 2462/4885L3MBTL1 1519/4885HPGD 1266/4885 |
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | MAPT 2462/4885L3MBTL1 1519/4885HPGD 1266/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | MAPT 2462/4885L3MBTL1 1519/4885HPGD 1266/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | MAPT 2462/4885L3MBTL1 1519/4885HPGD 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.